Antoni Ribas
University of California, Los Angeles
H-index: 159
North America-United States
Description
Antoni Ribas, With an exceptional h-index of 159 and a recent h-index of 125 (since 2020), a distinguished researcher at University of California, Los Angeles, specializes in the field of Oncology.
His recent articles reflect a diverse array of research interests and contributions to the field:
Correction: ERK mediates interferon gamma-induced melanoma cell death
A topical BRAF inhibitor (LUT-014) for treatment of radiodermatitis among women with breast cancer
The side effect registry immuno-oncology (SERIO)–A tool for systematic analysis of immunotherapy-induced side effects
Integrative systems biology reveals NKG2A-biased immune responses correlate with protection in infectious disease, autoimmune disease, and cancer
CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes
ERK mediates interferon gamma-induced melanoma cell death (vol 22, 165, 2023)
Biopsy analysis of trial S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with anti-PD-1 refractory melanoma
A phase 1 study of triple‐targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF‐mutated cancers
Professor Information
University | University of California, Los Angeles |
---|---|
Position | ___ |
Citations(all) | 161107 |
Citations(since 2020) | 89709 |
Cited By | 109397 |
hIndex(all) | 159 |
hIndex(since 2020) | 125 |
i10Index(all) | 544 |
i10Index(since 2020) | 413 |
University Profile Page | University of California, Los Angeles |
Research & Interests List
Oncology
Top articles of Antoni Ribas
Correction: ERK mediates interferon gamma-induced melanoma cell death
Correction: ERK mediates interferon gamma-induced melanoma cell death - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text Archive Search in PMC Advanced Search User Guide Journal List Mol Cancer v.23; 2024 PMC10840292 Other Formats PDF (630K) Actions Cite Collections Share Permalink Copy RESOURCES Similar articles Cited by other articles Links to NCBI Databases Journal List Mol Cancer v.23; 2024 PMC10840292 As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: PMC Disclaimer | PMC Copyright Notice Logo of molcanc Mol Cancer. 2024; 23: 29. Published online 2024 Feb 5. doi: 10.1186/s12943-024-01949-5 PMCID: …
Authors
Ameya Champhekar,Rachel Heymans,Justin Saco,Guillem Turon Font,Cynthia Gonzalez,Anne Gao,John Pham,June Lee,Ryan Maryoung,Egmidio Medina,Katie M Campbell,Daniel Karin,David Austin,Robert Damioseaux,Antoni Ribas
Journal
Molecular Cancer
Published Date
2024
A topical BRAF inhibitor (LUT-014) for treatment of radiodermatitis among women with breast cancer
BackgroundModern radiotherapy is associated with dermatitis (RD) in approximately one-third of patients treated for breast cancer. There is currently no standard for treating RD.ObjectiveThe objective of this study was to determine whether LUT014, a topical BRAF inhibitor which paradoxically activates mitogen-activated protein kinase, can safely improve RD.MethodsA phase I/II study was designed to first follow a small cohort of women with grade 2 RD regarding toxicity and response. Then, 20 patients were randomized to compare LUT014 to “vehicle” relative to safety and response (measured with common terminology criteria for adverse events, Dermatology Life Quality Index).ResultsNo substantial toxicity (eg, 0 serious adverse event) was associated with LUT014. All 8 women receiving LUT014 achieved treatment success (5-point Dermatology Life Quality Index reduction at day 14) compared to 73% (8/11) on …
Authors
Sanford Katz,Doug Ciuba,Antoni Ribas,Noa Shelach,Galit Zelinger,Briana Barrow,Benjamin W Corn
Journal
JAAD international
Published Date
2024/6/1
The side effect registry immuno-oncology (SERIO)–A tool for systematic analysis of immunotherapy-induced side effects
BackgroundImmunotherapies such as immune checkpoint inhibitors (ICI) are effective in multiple tumor entities but induce a plethora of side effects. Comprehensive real-world analyses are essential to identify new signals, characterize diagnostic features, enable risk assessment, determine pathomechanisms, assess effectiveness of side effect management and compare tumor outcomes.MethodsThe international online `Side-Effect Registry Immuno-Oncology´ (SERIO; www.serio-registry.org) collects rare, complex, and severe immunotherapy-induced side effects across all tumor entities with a strong focus on ICI-induced immune-related adverse events (irAE). The relational database management system (RDMS) contains structured data on patient and tumor characteristics, type of immunotherapy, treatment of side effects, and outcome of tumor and irAE. Data are captured within 25 organ modules including new …
Authors
Carolin Ertl,Theresa Ruf,Dirk Mentzer,Mingzi Kong,Rafaela Kramer,Michael von Bergwelt-Baildon,Marion Subklewe,Dirk Tomsitz,Paolo A Ascierto,Reinhard Dummer,Helen Gogas,Celeste Lebbé,Georgina V Long,Grant McArthur,Tomas G Neilan,Antoni Ribas,Caroline Robert,Dirk Schadendorf,Lisa Zimmer,Thomas Eigentler,Stephan Grabbe,Andrea Forschner,Katharina C Kähler,Valeria Milani,Claudia Pföhler,Jessica Hassel,Ralf Gutzmer,Carmen Loquai,Bertrand Routy,Andrew JS Furness,Christian Blank,Jedd D Wolchok,Lars E French,Axel Hauschild,Lucie Heinzerling
Journal
European Journal of Cancer
Published Date
2024/3/1
Integrative systems biology reveals NKG2A-biased immune responses correlate with protection in infectious disease, autoimmune disease, and cancer
Infection, autoimmunity, and cancer are principal human health challenges of the 21st century. Often regarded as distinct ends of the immunological spectrum, recent studies hint at potential overlap between these diseases. For example, inflammation can be pathogenic in infection and autoimmunity. T resident memory (TRM) cells can be beneficial in infection and cancer. However, these findings are limited by size and scope; exact immunological factors shared across diseases remain elusive. Here, we integrate large-scale deeply clinically and biologically phenotyped human cohorts of 526 patients with infection, 162 with lupus, and 11,180 with cancer. We identify an NKG2A+ immune bias as associative with protection against disease severity, mortality, and autoimmune/post-acute chronic disease. We reveal that NKG2A+ CD8+ T cells correlate with reduced inflammation and increased humoral immunity and …
Authors
Daniel G Chen,Jingyi Xie,Jongchan Choi,Rachel H Ng,Rongyu Zhang,Sarah Li,Rick Edmark,Hong Zheng,Ben Solomon,Katie M Campbell,Egmidio Medina,Antoni Ribas,Purvesh Khatri,Lewis L Lanier,Philip J Mease,Jason D Goldman,Yapeng Su,James R Heath
Journal
Cell Reports
Published Date
2024/3/26
CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes
A major limitation to developing chimeric antigen receptor (CAR)-T cell therapies for solid tumors is identifying surface proteins highly expressed in tumors but not in normal tissues. Here, we identify Tyrosinase Related Protein 1 (TYRP1) as a CAR-T cell therapy target to treat patients with cutaneous and rare melanoma subtypes unresponsive to immune checkpoint blockade. TYRP1 is primarily located intracellularly in the melanosomes, with a small fraction being trafficked to the cell surface via vesicular transport. We develop a highly sensitive CAR-T cell therapy that detects surface TYRP1 in tumor cells with high TYRP1 overexpression and presents antitumor activity in vitro and in vivo in murine and patient-derived cutaneous, acral and uveal melanoma models. Furthermore, no systemic or off-tumor severe toxicities are observed in an immunocompetent murine model. The efficacy and safety profile of the TYRP1 …
Authors
Sameeha Jilani,Justin D Saco,Edurne Mugarza,Aleida Pujol-Morcillo,Jeffrey Chokry,Clement Ng,Gabriel Abril-Rodriguez,David Berger-Manerio,Ami Pant,Jane Hu,Rubi Gupta,Agustin Vega-Crespo,Ignacio Baselga-Carretero,Jia M Chen,Daniel Sanghoon Shin,Philip Scumpia,Roxana A Radu,Yvonne Chen,Antoni Ribas,Cristina Puig-Saus
Journal
Nature Communications
Published Date
2024/2/9
ERK mediates interferon gamma-induced melanoma cell death (vol 22, 165, 2023)
BackgroundInterferon-gamma (IFNγ) exerts potent growth inhibitory effects on a wide range of cancer cells through unknown signaling pathways. We pursued complementary screening approaches to characterize the growth inhibition pathway.MethodsWe performed chemical genomics and whole genome targeting CRISPR/Cas9 screens using patient-derived melanoma lines to uncover essential nodes in the IFNγ-mediated growth inhibition pathway. We used transcriptomic profiling to identify cell death pathways activated upon IFNγ exposure. Live imaging experiments coupled with apoptosis assays confirmed the involvement of these pathways in IFNγ-mediated cell death.ResultsWe show that IFNγ signaling activated ERK. Blocking ERK activation rescued IFNγ-mediated apoptosis in 17 of 23 (~ 74%) cell lines representing BRAF, NRAS, NF1 mutant, and triple wild type subtypes of cutaneous melanoma. ERK …
Authors
Ameya Champhekar,Rachel Heymans,Justin Saco,Guillem Turon Font,Cynthia Gonzalez,Anne Gao,John Pham,June Lee,Ryan Maryoung,Egmidio Medina,Katie M Campbell,Daniel Karin,David Austin,Robert Damioseaux,Antoni Ribas
Journal
Molecular Cancer
Published Date
2023/10/6
Biopsy analysis of trial S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with anti-PD-1 refractory melanoma
Background: The phase II randomized trial S1616 (NCT03033576) showed that patients with melanoma refractory to anti-PD-1-based therapy had improved progression free survival (HR=0.63, p=0.037) and objective response (28% vs 9%) to the combination of ipilimumab with nivolumab compared to ipilimumab. Here, we report molecular and spatial proteomic features of biopsies collected from patients on S1616, both prior to and during therapy. Methods: Biopsies collected from patients from both arms at baseline (N=68 patients total) and early on-therapy (N=51; 43 with paired timepoints) were analyzed by whole exome sequencing (n=185 samples), RNA sequencing (n=105), histopathologic staining (n=149), and multiplexed ion beam imaging (n=45). Multiple biopsies were available for some patients. Mutations, gene expression, and tumor microenvironment were compared across timepoints and response …
Authors
Katie M Campbell,Zaid Bustami,Daniel G Chen,Egmidio Medina,Cynthia R Gonzalez,Nataly Naser Aldeen,Ignacio Baselga-Carretero,Agustin Vega-Crespo,Jessica Maxey,Jia M Chen,Lawrence F Kuklinski,Kari L Kendra,Bartosz Chmielowski,Thach-Giao Truong,Nikhil I Khushalani,Frances Collichio,Alexandra Ikeguchi,Adrienne I Victor,Kim Margolin,Jeffrey A Sosman,Sapna P Patel,Siwen Hu-Lieskovan,James Moon,Shay Bellasea,Daniel K Wells,Christine N Spencer,Marshall A Thompson,Michael Wu,Philip O Scumpia,Ari VanderWalde,Antoni Ribas
Journal
Cancer Research
Published Date
2024/3/22
A phase 1 study of triple‐targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF‐mutated cancers
Background Aberrant PI3K/AKT signaling in BRAF‐mutant cancers contributes to resistance to BRAF inhibitors. The authors examined dual MAPK and PI3K pathway inhibition in patients who had BRAF‐mutated solid tumors (ClinicalTrials.gov identifier NCT01902173). Methods Patients with BRAF V600E/V600K–mutant solid tumors received oral dabrafenib at 150 mg twice daily with dose escalation of oral uprosertib starting at 50 mg daily, or, in the triplet cohorts, with dose escalation of both oral trametinib starting at 1.5 mg daily and oral uprosertib starting at 25 mg daily. Dose‐limiting toxicities (DLTs) were assessed within the first 56 days of treatment. Radiographic responses were assessed at 8‐week intervals. Results Twenty‐seven patients (22 evaluable) were enrolled in parallel doublet and triplet cohorts. No DLTs were observed in the doublet cohorts (N = 7). One patient had a DLT at the maximum …
Authors
Alain P Algazi,James Moon,Christopher D Lao,Bartosz Chmielowski,Kari L Kendra,Karl D Lewis,Rene Gonzalez,Kevin Kim,John E Godwin,Brendan D Curti,Michaella Latkovic‐Taber,Shirley H Lomeli,Brandon T Gufford,Philip O Scumpia,Roger S Lo,Megan Othus,Antoni Ribas
Journal
Cancer
Published Date
2024/1/23
Professor FAQs
What is Antoni Ribas's h-index at University of California, Los Angeles?
The h-index of Antoni Ribas has been 125 since 2020 and 159 in total.
What are Antoni Ribas's top articles?
The articles with the titles of
Correction: ERK mediates interferon gamma-induced melanoma cell death
A topical BRAF inhibitor (LUT-014) for treatment of radiodermatitis among women with breast cancer
The side effect registry immuno-oncology (SERIO)–A tool for systematic analysis of immunotherapy-induced side effects
Integrative systems biology reveals NKG2A-biased immune responses correlate with protection in infectious disease, autoimmune disease, and cancer
CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes
ERK mediates interferon gamma-induced melanoma cell death (vol 22, 165, 2023)
Biopsy analysis of trial S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with anti-PD-1 refractory melanoma
A phase 1 study of triple‐targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF‐mutated cancers
...
are the top articles of Antoni Ribas at University of California, Los Angeles.
What are Antoni Ribas's research interests?
The research interests of Antoni Ribas are: Oncology
What is Antoni Ribas's total number of citations?
Antoni Ribas has 161,107 citations in total.